These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Should patients with pulmonary hypertension and increased pulmonary resistance be treated with vasodilators? Rich S Cardiovasc Clin; 1990; 21(1):265-74; discussion 275-6. PubMed ID: 2199052 [No Abstract] [Full Text] [Related]
28. The response to inhaled nitric oxide in patients with pulmonary artery hypertension is not masked by baseline vasodilator use. Krasuski RA; Wang A; Harrison JK; Tapson VF; Bashore TM Am Heart J; 2005 Oct; 150(4):725-8. PubMed ID: 16209974 [TBL] [Abstract][Full Text] [Related]
29. Hemolytic anemia-associated pulmonary hypertension of sickle cell disease and the nitric oxide/arginine pathway. Jison ML; Gladwin MT Am J Respir Crit Care Med; 2003 Jul; 168(1):3-4. PubMed ID: 12826592 [No Abstract] [Full Text] [Related]
30. Treatment of chronic pulmonary hypertension by vasodilators. Symposium: E.S.C. Working Group on Pulmonary Circulation. 9 September 1987, Santiago de Compostela, Spain.Proceedings. Eur Heart J; 1988 Sep; 9 Suppl J():1-43. PubMed ID: 3181181 [No Abstract] [Full Text] [Related]
31. Modulating the pulmonary circulation: an update. Dembinski R; Henzler D; Rossaint R Minerva Anestesiol; 2004 Apr; 70(4):239-43. PubMed ID: 15173703 [TBL] [Abstract][Full Text] [Related]
32. [Heart pathology of extracardiac origin. IV. Pulmonary hypertension in chronic respiratory diseases]. Barberà JA Rev Esp Cardiol; 1998 Jan; 51(1):56-68. PubMed ID: 9522610 [TBL] [Abstract][Full Text] [Related]
33. [Effects of vasodilators on pulmonary hypertension]. Uotani K; Kanamori K; Fujimura M; Mifune J; Taga K; Shimizu M; Hifumi S; Takahashi Y; Azuma H; Tanaka T Kokyu To Junkan; 1986 Sep; 34(9):977-83. PubMed ID: 3786964 [No Abstract] [Full Text] [Related]
34. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Madden BP; Allenby M; Loke TK; Sheth A Vascul Pharmacol; 2006 May; 44(5):372-6. PubMed ID: 16574495 [TBL] [Abstract][Full Text] [Related]
35. [Impact of 30 day therapy with doxazosin--alpha1 adrenergic blocker on pulmonary hemodynamics in patients with secondary pulmonary hypertension due to chronic obstructive pulmonary disease]. Lewczuk J; Piszko P; Jagas J; Wrabec K Pol Merkur Lekarski; 2005 Mar; 18(105):279-81. PubMed ID: 15997632 [TBL] [Abstract][Full Text] [Related]
36. Vasodilators in pulmonary hypertension. Peacock A Thorax; 1993 Dec; 48(12):1196-9. PubMed ID: 8303622 [No Abstract] [Full Text] [Related]
37. [Modification of pulmonary hypertension in patients with chronic obstructive lung diseases using calcium antagonists in an acute trial]. Schauer J; Himmel W; Orschekowski H Z Gesamte Inn Med; 1989 Jan; 44(2):50-4. PubMed ID: 2650472 [TBL] [Abstract][Full Text] [Related]
38. Pulmonary hypertension in systemic lupus erythematosus: effect of vasodilators on pulmonary hemodynamics. Mahowald ML; Weir EK; Ridley DJ; Messner RP J Rheumatol; 1985 Aug; 12(4):773-7. PubMed ID: 4057200 [TBL] [Abstract][Full Text] [Related]
39. Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again. Prins KW; Thenappan T; Weir EK; Kalra R; Pritzker M; Archer SL J Am Heart Assoc; 2019 Jan; 8(1):e011343. PubMed ID: 30590974 [No Abstract] [Full Text] [Related]
40. Treatment of pulmonary hypertension with selective pulmonary vasodilators. Haj RM; Cinco JE; Mazer CD Curr Opin Anaesthesiol; 2006 Feb; 19(1):88-95. PubMed ID: 16547439 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]